Drug-resistant tuberculosis in Egyptian children using Etest

Minerva Pediatrica

Volumn 60, Issue 6, 2008, Pages 1385-1392

  Morcos, W ^a   Morcos, M Mikhail ^a,c   Doss, S ^b   Naguib, M ^b   Eissa, S ^b  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c NONE   (United Arab Emirates)

Author keywords

Egypt; Extensively drug resistant TB; Mycobacterium TB

Indexed keywords

AMIKACIN; CIPROFLOXACIN; ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTHROPATHY; ARTICLE; ASCITES; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BONE DISEASE; CHILD; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESISTANT TUBERCULOSIS; EGYPT; EPSILOMETER TEST; HUMAN; LUNG TUBERCULOSIS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MENINGITIS; MILIARY TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEURA EFFUSION; PNEUMONIA; PREVALENCE; RADIOGRAPHY; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST;

ANTITUBERCULAR AGENTS; CHI-SQUARE DISTRIBUTION; CHILD; DRUG RESISTANCE, BACTERIAL; EGYPT; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; PROSPECTIVE STUDIES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 57749174078     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Anti-tuberculosis drug resistance in the world: Report 2; Prevalence and trends Global Project on Anti-tuberculosis Drug Resistance Surveillance. 2000,1-253 World Health Organization. Geneva, Switzerland: document WHO/CDS/TB/2000.278
2. Schaaf HS, Gie RP, Beyers N, Sirgel FA, de Klerk PJ, Donald PR. Primary drug-resistant tuberculosis in children Int J Tuberc Lung Dis 2000;4:1149-55
3. Al-Dossary FS, Ong LT, Correa AG, Starke JR. Treatment of childhood tuberculosis with a six month directly observed regimen of only two weeks of daily therapy. Pediatr Infect Dis J 2002;21:91-7.
4. th edition. Baltimore: Williams and Wilkins; 1996. p. 127-75.
5. Hazbon MH, del Socorro Orozco M, Labrada LA, Tovar R. Weigle KA, Wanger A. Evaluation of E-test for Susceptibility testing of multi-drug resistant isolates of Mycobacterium tuberculosis. J Clin Microbiol 2000;38:4599-603.
6. Wanger A and Mills K. Testing of Mycobacterium tuberculosis susceptibility to Ethambutol. Isoniazid. Rifampicin and Streptomycin by using E-test. J Clin Microbiol 1996;34:1672-6.
7. Joloba ML. Bajaksouzian S, Jacobs MR. Evaluation of Etest for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2000;38:38:3834-6.
8. Freixo IM, Caldas PC, Martins F, Brito RC, Ferreira RM, Fonseca LS et al. Evaluation of Etest strips for rapid susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2002;40:2282-4.
9. American Thoracic Society Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000;161:1376-95.
10. Mantoux C. Intradermo-réaction de la tuberculine. Comptes rendus de l'Académie des sciences. Paris 1908;147:355-7.
11. Steiner P, Rao M, Mitchell M, Steiner M. Primary drug resistant tuberculosis in children. Correlation of drug-susceptibility patterns of matched patient and source case strains of Mycobacterium tuberculosis. Am J Dis Child 1985;139:780-2.
12. th edition. Washington: ASM Press; 1999. p. 399-437.
13. Kent PT and Kubica. Public Health Mycobacteriology: a guide for the level III laboratory. Atlanta Ga: CDC; 1985. p. 71-120.
14. Johansen IS, Larsen AR, Sandven P, Petrini B, Soini H, Levina K et al. Drug susceptibility testing of Mycobacterium tuberculosis to fluoroquinolones: first experience with a quality control panel in the Nordic-Baltic collaboration. Int J Tuberc Lung Dis 2003;7:899-902.
15. Rodríguez JC, Ruiz M, Climent A, Royo G. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents 2001;17:229-31.
16. Ho YI, Chan CY, Cheng AF. In vitro activities of aminoglycoside- aminocyclitols against mycobacteria. J Antimicrob Chemother 1997;40:27-32.
17. Jekel J, Elomore G and Katz DL. Epidemiology, biostatistics and preventive medicine. Philadelphia: WB Saunders Co; 1996. p. 89-102.
18. Kassa Kelembho E, Bobossi Serengbe G, Takeng EC, Nambea Koisse TB, Yapou F, Talarmin A. Surveillance of drug-resistant childhood tuberculosis in Bangui, Central African Republic. Int J Tuberc Lung Dis 2004;8:574-8.
19. Weyer K, Groenewald P, Zwarenstein M, Lombard CJ. Tuberculosis drug resistance in the Western Cape. S Afr Med J 1995;85:499-504.
20. World Health Organization / International Union against Tuberculosis and Lung Disease (WHO/IUTLD) 1994 Guidelines for surveillance of drug resistance in tuberculosis WHO/TB/94.178 Geneva, Switzerland WHO. 2004 [Internet] http://whqlibdoc.who.int/publications/2004/9241562854_chap4.pdf [cited October 7, 2008]
21. World Health Organization Global Tuberculosis Control Program/ Country profile / Egypt. 2005. WHO, Geneva Switzerland
22. Dilber E, Gocman A, Kiper N, Ozcelik U. Drug resistant Tuberculosis in Turkish Children Turk J Pediatr 2000;42:145-7.
23. Kam KM and Yip CW. Surveillance of Mycobacterium tuberculosis susceptibility to second line drugs in Hong Kong. 1995-2002, after the implementation of the DOTS-plus. Int J Tuberc Lung Dis 2004;8:760-6.
24. Cavusoglu C, Cicek-Saydam C, Burhanoglu D, Ozkalay N, Ozkaya D, Ozcam H et al. Comparison of standard proportion dilution test and Etest for Mycobacterium tuberculosis sensitivity to ofloxacin and ciprofloxacin. Mikrobiyol Bul 2002;36:118-23.
25. Marinis E, Legakis NJ. In-vitro activity of ciprofloxacin against clinical isolates of mycobacteria resistant to antimycobacterial drugs. J Antimicrob Chemother 1985;16:527-30.
26. Hessein R, Mostafa R, and Youssef A. Isoniazid (INH) and Rifampicin resistance in patients with pulmonary tuberculosis with special reference to atypical mycobacterium infection. Egyp J Chest Dis Tuberc 2000;49:183-93.
27. El Gazzar AG, Hamdy AB, Eissa SA, Youssef AA, El Aarag AS, Enan A et al. Initial Drug resistance to antituberculous drugs in Qualioubeya Governorate, Egypt. Egy J Chest Dis Tuberc 1996;45:39-48.
28. Wanger A, Mills K. Etest for susceptibility testing of Mycobacterium tuberculosis and Mycobacterium avium intracellulare. Diag Microbiol Infect Dis 1994;19:179-81.
29. Hausdorfer J, Sompek E, Allerberger F, Dierich MP, Rüsch-Gerdes S. E-test for. susceptibility testing of Mycobacterium tuberculosis. Int J. Tuberc Lung Dis 1998;2:751-5
30. Akcali S, Cicek C, Surucuoglu S, Ozbakkaloglu B. E-Test: An Alternative Method for Susceptibility Testing of Mycobacterium tuberculosis. Med Princ Pract 2005;14:264-7.
31. Delas M, Martinez C, Yague C, Rodriguez T, Segovia M. Comparative study of three tests for susceptibility of M. Tuberculosis to first line antituberculous drugs. Rev Esp Quimioter 2001;14:40-6.
32. Freixo IM, Caldas PC, Martins F, Brito RC, Ferreira RM, Fonseca LS et al. Evaluation of E-test strips for rapid susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2002;40:2282-4.
33. Fabry W, Schmid EN and Ansorg R. Comparison of Etest and proportion dilution method for susceptibility testing of myco bacterium tuberculosis. Zentralbl Bakteriol 1995;282:394-401.
34. Freixo MI, Caldas PC, Said A, Martins F, Brito RC, Fonseca Lde S et al. Antimicrobial Susceptibility Determined by the E Test, Löwenstein-Jensen Proportion, and DNA Sequencing Methods among Mycobacterium tuberculosis Isolates - Discrepancies, Preliminary Results Mem Inst Oswaldo Cruz 2004;99:107-10.